Spero Therapeutics Receives FDA Orphan Drug Designation for SPR720 for the Treatment of Nontuberculous Mycobacterial (NTM) Infection

    NEXT STORY
    Jackson Memorial Hospital gives Philips Enterprise Monitoring as a Service model high marks for satisfaction and efficiency
    PREV STORY
    I-Mab to Report Financial Results for Full Year 2019 and Provide Corporate Update on March 31, 2020
    Subscribe to PM360
    Print Subscription
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    NewLink Genetics Presents Updated NLG802 Results at the Immuno-Oncology 2019 World Congress

    author_avatar
    NASDAQ Market News

    Mapi Pharma to Host Key Opinion Leader Meeting on Long Acting Glatiramer Acetate (GA Depot) for Multiple Sclerosis

    NESS ZIONA, Israel, Feb. 06, 2018 (GLOBE NEWSWIRE) -- Mapi Pharma Ltd., a fully ...

    author_avatar
    NASDAQ Market News

    North America Sports Medicine Market 2020-2030: Consistent Innovation of New Products and Treatment Modalities

    author_avatar
    NASDAQ Market News